Abstract
Background: Hematopoietic stem cell transplantation (HSCT) survivors are at higher risk of developing adverse cardiovascular risk (CVR) and metabolic syndrome, leading to cardiovascular comorbidities. The aim of this study was to evaluate the CVR in patients before and after HSCT.
Methods: We conducted an analytical and observational retrospective cohort of adult patients treated with autologous and allogeneic HSCT at a fourth level referral center in Colombia from 2009 to 2018. To calculate CVR, metabolic syndrome, hypertriglyceridemia, low HDL cholesterol, hypercholesterolemia, atherogenic dyslipidemia, overweight, obesity, prediabetes, diabetes mellitus, hypertension and hyperuricemia were evaluated. Cardiovascular risk was measured before and one year after HSCT with Framingham scale, a gender-specific algorithm used to estimate the 10-year cardiovascular risk.
Results: Information from 103 patients were analyzed for CVR before HSCT, and information from 55 patients were available for CVR after 1 year of HSCT. Before HSTC, low CVR was identified in 69 patients (67%), moderate CVR in 26 patients (25%) and high CVR in 8 patients (8%). After one-year follow-up, low CVR was identified in 36 patients (66%), moderate CVR in 14 patients (25%) and high CVR in 5 patients (9%). Average CVR by Framingham was 12.1% before HSCT and 12.86% one-year after HSCT.
Conclusions: It is clear that HSCT survivors have a higher prevalence of cardiovascular disease, HSCT survivors presented a Framingham score of 10-20%, which is categorized by the American Heart Association (AHA) as intermediate CVR, which remained even one year after HSCT. This exposes the need of aggressive screening for CVR such metabolic syndrome to establish prevention strategies and decrease morbidity, poor quality of life, and premature mortality.
Methods: We conducted an analytical and observational retrospective cohort of adult patients treated with autologous and allogeneic HSCT at a fourth level referral center in Colombia from 2009 to 2018. To calculate CVR, metabolic syndrome, hypertriglyceridemia, low HDL cholesterol, hypercholesterolemia, atherogenic dyslipidemia, overweight, obesity, prediabetes, diabetes mellitus, hypertension and hyperuricemia were evaluated. Cardiovascular risk was measured before and one year after HSCT with Framingham scale, a gender-specific algorithm used to estimate the 10-year cardiovascular risk.
Results: Information from 103 patients were analyzed for CVR before HSCT, and information from 55 patients were available for CVR after 1 year of HSCT. Before HSTC, low CVR was identified in 69 patients (67%), moderate CVR in 26 patients (25%) and high CVR in 8 patients (8%). After one-year follow-up, low CVR was identified in 36 patients (66%), moderate CVR in 14 patients (25%) and high CVR in 5 patients (9%). Average CVR by Framingham was 12.1% before HSCT and 12.86% one-year after HSCT.
Conclusions: It is clear that HSCT survivors have a higher prevalence of cardiovascular disease, HSCT survivors presented a Framingham score of 10-20%, which is categorized by the American Heart Association (AHA) as intermediate CVR, which remained even one year after HSCT. This exposes the need of aggressive screening for CVR such metabolic syndrome to establish prevention strategies and decrease morbidity, poor quality of life, and premature mortality.
| Original language | English |
|---|---|
| Pages (from-to) | 426-427 |
| Journal | Bone Marrow Transplantation |
| Volume | 55 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 2020 |